Protalix BioTherapeutics
PLX
66 hedge funds and large institutions have $18M invested in Protalix BioTherapeutics in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 21 increasing their positions, 16 reducing their positions, and 7 closing their positions.
556% more call options, than puts
Call options by funds: $984K | Put options by funds: $150K
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
31% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 16
18% more capital invested
Capital invested by funds: $15.2M → $18M (+$2.79M)
8% more funds holding
Funds holding: 61 → 66 (+5)
1.06% more ownership
Funds ownership: 12.81% → 13.86% (+1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$467K |
| 2 |
BlackRock
New York
|
+$439K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$161K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$136K |
| 5 |
Barclays
London,
United Kingdom
|
+$123K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$229K |
| 2 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$150K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$101K |
| 4 |
SOW
State of Wyoming
Cheyenne,
Wyoming
|
-$68.5K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$45.9K |
PLX Hedge Fund Activity: Q4 2023 in Review
66 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2023, worth a combined $18M — up 18% from $15.2M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PLX positions and 7 closed out — a net gain of 5 holders — while 21 added to existing stakes and 16 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $467K. The largest seller was Allspring Global Investments, exiting entirely with an estimated $229K sold.
- 66 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2023, up from 61 in Q3 2023.
- Funds reported $18M of Protalix BioTherapeutics stock for Q4 2023, up 18% quarter-over-quarter.
- 12 funds opened new Protalix BioTherapeutics positions in Q4 2023 and 7 closed out, a net change of +5 holders.
- The largest Protalix BioTherapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $467K added.
- The largest Protalix BioTherapeutics seller in Q4 2023 was Allspring Global Investments, an estimated $229K sold.
Based on aggregated 13F filings for Q4 2023.